Guidelines for Acromegaly Management: An Update, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.5, 2009. ,
DOI : 10.1210/jc.2008-2421
Determinants of clinical outcome and survival in acromegaly, Clinical Endocrinology, vol.153, issue.4, 1994. ,
DOI : 10.2307/2281868
Mortality and Cancer Incidence in Acromegaly, The Journal of Urology, vol.83, issue.8, pp.2730-2734, 1998. ,
DOI : 10.1097/00005392-199904000-00103
Mortality in Acromegaly: A Metaanalysis, The Journal of Clinical Endocrinology & Metabolism, vol.93, issue.1, pp.61-68, 2008. ,
DOI : 10.1210/jc.2007-1191
Surgical Interventions and Medical Treatments in Treatment-Na??ve Patients With Acromegaly: Systematic Review and Meta-Analysis, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.11, 2014. ,
DOI : 10.1210/jc.2014-2900
Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly, Journal of Neurosurgery, vol.89, issue.3, pp.353-361, 1998. ,
DOI : 10.3171/jns.1998.89.3.0353
An Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab Oct, vol.3099, issue.11, pp.3933-51, 2014. ,
Long-Term Results of Stereotactic Radiosurgery in Secretory Pituitary Adenomas, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.9, pp.3400-3407, 2009. ,
DOI : 10.1210/jc.2008-2772
Radiotherapy and radiosurgery in acromegaly, Pituitary, vol.4, issue.Suppl 3, pp.3-10, 2009. ,
DOI : 10.1007/s11102-007-0078-y
Risk of Second Brain Tumor after Conservative Surgery and Radiotherapy for Pituitary Adenoma: Update after an Additional 10 Years, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.2, pp.800-804, 2005. ,
DOI : 10.1210/jc.2004-1152
Conventional Pituitary Irradiation Is Effective in Lowering Serum Growth Hormone and Insulin-Like Growth Factor-I in Patients with Acromegaly, The Journal of Clinical Endocrinology & Metabolism, vol.91, issue.4, pp.1239-1284, 2006. ,
DOI : 10.1210/jc.2005-1616
Place of Cabergoline in Acromegaly: A Meta-Analysis, The Journal of Clinical Endocrinology & Metabolism, vol.96, issue.5 ,
DOI : 10.1210/jc.2010-2443
Expert consensus document: A consensus on the medical treatment of acromegaly, Nature Reviews Endocrinology, vol.161, issue.4 ,
DOI : 10.1038/nrendo.2014.21
Treatment of Acromegaly with the Growth Hormone???Receptor Antagonist Pegvisomant, New England Journal of Medicine, vol.342, issue.16, pp.1171-1178, 2000. ,
DOI : 10.1056/NEJM200004203421604
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist, The Lancet, vol.358, issue.9295, pp.1754-1763, 2001. ,
DOI : 10.1016/S0140-6736(01)06844-1
Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY, The Journal of Clinical Endocrinology & Metabolism, vol.97, issue.5, pp.1589-97, 2012. ,
DOI : 10.1210/jc.2011-2508
URL : https://hal.archives-ouvertes.fr/hal-00701564
Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: Safety and efficacy evaluation from the German Pegvisomant Observational Study, European Journal of Endocrinology, vol.156, issue.1, pp.75-82, 2007. ,
DOI : 10.1530/eje.1.02312
Guidelines for Acromegaly Management: An Update, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.5, 2009. ,
DOI : 10.1210/jc.2008-2421
Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly, The Lancet, vol.365, issue.9471, pp.1644-1650, 2005. ,
DOI : 10.1016/S0140-6736(05)63011-5
ACROSTUDY: the first 5 years, European Journal of Endocrinology, vol.161, issue.Suppl 1, pp.19-24, 2009. ,
DOI : 10.1530/EJE-09-0322
Cotreatment of Acromegaly with a Somatostatin Analog and a Growth Hormone Receptor Antagonist, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.10, pp.5627-5658, 2005. ,
DOI : 10.1210/jc.2005-0531
Long-Term Efficacy and Safety of Combined Treatment of Somatostatin Analogs and Pegvisomant in Acromegaly, The Journal of Clinical Endocrinology & Metabolism, vol.92, issue.12, 2007. ,
DOI : 10.1210/jc.2007-1234
Quality of Life in Acromegalic Patients during Long-Term Somatostatin Analog Treatment with and without Pegvisomant, The Journal of Clinical Endocrinology & Metabolism, vol.93, issue.10, 2008. ,
DOI : 10.1210/jc.2008-0669
Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients, European Journal of Endocrinology, vol.160, issue.4, pp.529-562, 2009. ,
DOI : 10.1530/EJE-08-0843
A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly, Clinical Endocrinology, vol.87, issue.4, pp.549-57, 2009. ,
DOI : 10.1111/j.1365-2265.2009.03620.x
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients. Pituitary, pp.253-261, 2011. ,
Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone, European Journal of Endocrinology, vol.164, issue.3, pp.325-358, 2011. ,
DOI : 10.1530/EJE-10-0867
Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes, Journal of Experimental & Clinical Cancer Research, vol.32, issue.1, p.40, 2013. ,
DOI : 10.1210/jc.2010-1742
Long-Term Efficacy and Safety of Pegvisomant in Combination With Long-Acting Somatostatin Analogs in Acromegaly, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.10, 2014. ,
DOI : 10.1210/jc.2014-2032
AcroBel the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects, European Journal of Endocrinology, vol.157, issue.4, pp.399-409, 2007. ,
DOI : 10.1530/EJE-07-0358
Growth Hormone and Pituitary Radiotherapy, But Not Serum Insulin-Like Growth Factor-I Concentrations, Predict Excess Mortality in Patients with Acromegaly, The Journal of Clinical Endocrinology & Metabolism, vol.89, issue.4, pp.1613-1620, 2004. ,
DOI : 10.1210/jc.2003-031584
A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly, European Journal of Endocrinology, vol.159, issue.2, pp.89-95, 2008. ,
DOI : 10.1530/EJE-08-0267
Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA), European Journal of Endocrinology, vol.151, issue.4, pp.439-485, 2004. ,
DOI : 10.1530/eje.0.1510439
A Paradigm Shift in the Monitoring of Patients With Acromegaly: Last Available Growth Hormone May Overestimate Risk, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.2, pp.478-85, 2014. ,
DOI : 10.1210/jc.2013-2450
Treatment of Acromegaly, Hormone Research in Paediatrics, vol.62, issue.3, pp.79-92, 2004. ,
DOI : 10.1159/000080505
Factors Influencing Mortality in Acromegaly, The Journal of Clinical Endocrinology & Metabolism, vol.89, issue.2, pp.667-74, 2004. ,
DOI : 10.1210/jc.2003-031199
A Nationwide Survey of Mortality in Acromegaly, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.7, pp.4081-4087, 2005. ,
DOI : 10.1210/jc.2004-1381
Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management, Endocrine Reviews, vol.25, issue.1, pp.102-52, 2004. ,
DOI : 10.1210/er.2002-0022
Improvement of cardiac parameters in patients with acromegaly treated with medical therapies. Pituitary, pp.50-58, 2012. ,
Systemic Hypertension and Impaired Glucose Tolerance Are Independently Correlated to the Severity of the Acromegalic Cardiomyopathy, Journal of Clinical Endocrinology & Metabolism, vol.85, issue.1, pp.193-202, 2000. ,
DOI : 10.1210/jc.85.1.193
Risk Factors for Development of Coronary Heart Disease in Patients with Acromegaly: A Five-Year Prospective Study, The Journal of Clinical Endocrinology & Metabolism, vol.92, issue.11, pp.4271-4278, 2007. ,
DOI : 10.1210/jc.2007-1213
Cardiovascular Risk Factors in Patients with Uncontrolled and Long-Term Acromegaly: Comparison with Matched Data from the General Population and the Effect of Disease Control, The Journal of Clinical Endocrinology & Metabolism, vol.95, issue.8, pp.3648-56, 2010. ,
DOI : 10.1210/jc.2009-2570
Acromegaly: evidence for a direct relation between disease activity and cardiac dysfunction in patients without ventricular hypertrophy, Clinical Endocrinology, vol.260, issue.5, 2002. ,
DOI : 10.1016/0735-1097(95)00505-6
Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study, European Journal of Endocrinology, vol.173, issue.5, p.2015 ,
DOI : 10.1530/EJE-15-0500
Premature mortality due to cardiovascular disease in hypopituitarism, The Lancet, vol.336, issue.8710, pp.285-293, 1990. ,
DOI : 10.1016/0140-6736(90)91812-O
Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly, Clinical Endocrinology, vol.11, issue.1, pp.74-81, 2009. ,
DOI : 10.1111/j.1365-2265.2008.03461.x
Effects of growth hormone on glucose metabolism, Horm Res, vol.36, issue.1, pp.32-37, 1991. ,
Diabetes-Haufigkeit bei Akromegalie und Cushing-Syndrom, Acta Medica Austriaca, vol.27, issue.1, pp.27-31, 2000. ,
DOI : 10.1046/j.1563-2571.2000.00106.x
Prevalence of diabetes mellitus in patients with acromegaly, Endocrine Connections, vol.3, issue.2, pp.93-101, 2014. ,
DOI : 10.1530/EC-14-0021
Effects of Somatostatin Analogs on Glucose Homeostasis: A Metaanalysis of Acromegaly Studies, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.5, pp.1500-1508, 2009. ,
DOI : 10.1210/jc.2008-2332
Glucose Tolerance and Somatostatin Analog Treatment in Acromegaly: A 12-Month Study, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.8, pp.2907-2921, 2009. ,
DOI : 10.1210/jc.2008-2627
Successful treatment of resistant acromegaly with a growth hormone receptor antagonist, European Journal of Endocrinology, vol.145, issue.4, pp.451-457, 2001. ,
DOI : 10.1530/eje.0.1450451
Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA), European Journal of Endocrinology, vol.151, issue.4, pp.439-485, 2004. ,
DOI : 10.1530/eje.0.1510439
Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study, European Journal of Endocrinology, vol.173, issue.5, p.2015 ,
DOI : 10.1530/EJE-15-0500
Elevated incidence of sleep apnoea in acromegaly-correlation to disease activity. Sleep Breath Schlaf Atm, pp.1247-53, 2012. ,
Acromegalic arthropathy. Pituitary, pp.263-267, 2001. ,
Bone Turnover, Bone Mineral Density, and Fracture Risk in Acromegaly: A Meta-Analysis, The Journal of Clinical Endocrinology & Metabolism, vol.100, issue.2, pp.384-94, 2015. ,
DOI : 10.1210/jc.2014-2937
Effects of a growth hormone receptor antagonist on bone markers in acromegaly, Clinical Endocrinology, vol.84, issue.3, pp.385-90, 2002. ,
DOI : 10.1056/NEJM200004203421604
Colonoscopic Screening and Follow-Up in Patients with Acromegaly: A Multicenter Study in Italy, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.1, pp.84-90, 2005. ,
DOI : 10.1210/jc.2004-0240
The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance, Endocrine Reviews, vol.24, issue.1, pp.28-47, 2003. ,
DOI : 10.1210/er.2000-0001
Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas, European Journal of Endocrinology, vol.156, issue.1, pp.65-74, 2007. ,
DOI : 10.1530/eje.1.02313
Somatostatin agonists for treatment of acromegaly, Molecular and Cellular Endocrinology, vol.286, issue.1-2, pp.192-200, 2008. ,
DOI : 10.1016/j.mce.2007.11.024
Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.3, pp.791-800, 2014. ,
DOI : 10.1210/jc.2013-2480
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial, The Lancet Diabetes & Endocrinology, vol.2, issue.11, pp.875-84, 2014. ,
DOI : 10.1016/S2213-8587(14)70169-X
Medical progress: Acromegaly, N Engl J Med Dec, vol.14355, issue.24, pp.2558-73, 2006. ,
Acromegaly: Assessing the Disorder and Navigating Therapeutic Options for Treatment, Endocrine Practice, vol.20, issue.Supplement 1, pp.7-17, 2014. ,
DOI : 10.4158/EP14430.RA
Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis, PloS One, vol.8, issue.4, p.61523, 2013. ,
Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study, Endocrine Journal, vol.57, issue.12, pp.1035-1079, 2010. ,
DOI : 10.1507/endocrj.K10E-203
Preoperative Octreotide Treatment in Newly Diagnosed Acromegalic Patients with Macroadenomas Increases Cure Short-Term Postoperative Rates: A Prospective, Randomized Trial, The Journal of Clinical Endocrinology & Metabolism, vol.93, issue.8, pp.2984-90, 2008. ,
DOI : 10.1210/jc.2008-0315
Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial, European Journal of Endocrinology, vol.162, issue.4, pp.661-667, 2010. ,
DOI : 10.1530/EJE-09-0908
Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide, Clinical Endocrinology, vol.87, issue.6, pp.970-975, 2008. ,
DOI : 10.1111/j.1365-2265.2006.02467.x
Partial Surgical Removal of Growth Hormone-Secreting Pituitary Tumors Enhances the Response to Somatostatin Analogs in Acromegaly, The Journal of Clinical Endocrinology & Metabolism, vol.91, issue.1, 2006. ,
DOI : 10.1210/jc.2005-1208
Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?, Clinical Endocrinology, vol.67, issue.2 ,
DOI : 10.1210/jc.83.10.3411
Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs, European Journal of Endocrinology, vol.152, issue.1, 2005. ,
DOI : 10.1530/eje.1.01824
Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study., The Journal of Clinical Endocrinology & Metabolism, vol.80, issue.9, 1995. ,
DOI : 10.1210/jcem.80.9.7673422
The Antitumoral Effects of Somatostatin Analog Therapy in Acromegaly, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.3, pp.1856-63, 2005. ,
DOI : 10.1210/jc.2004-1093
UKAR-3) Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists, Clin Endocrinol, vol.79, issue.5, pp.689-99, 2013. ,
Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly, Clinical Endocrinology, vol.83, issue.1, pp.72-80 ,
DOI : 10.1111/j.1365-2265.2011.04286.x
Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly, Endocrine, vol.95, issue.7, pp.333-376, 2016. ,
DOI : 10.1007/s12020-015-0766-8
Primary Treatment of Acromegaly with Octreotide LAR: A Long-Term (Up to Nine Years) Prospective Study of Its Efficacy in the Control of Disease Activity and Tumor Shrinkage, The Journal of Clinical Endocrinology & Metabolism, vol.91, issue.4 ,
DOI : 10.1210/jc.2005-2347
Beneficial effect of dose escalation of Octreotide-LAR as first-line therapy in patients with acromegaly, European Journal of Endocrinology, vol.157, issue.5, pp.579-87, 2007. ,
DOI : 10.1530/EJE-07-0383
Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.3, pp.791-800, 2014. ,
DOI : 10.1210/jc.2013-2480
(long-acting repeatable octreotide) in the primary therapy of patients with acromegaly, Clinical Endocrinology, vol.29, issue.6, pp.859-68, 2007. ,
DOI : 10.1210/jc.85.2.781
Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel?? therapy: a randomized, placebo-controlled, multicenter study with a 52??week open extension, Pituitary, vol.94, issue.1, pp.18-28, 2010. ,
DOI : 10.1007/s11102-009-0191-1
Long-Acting Somatostatin Analog Therapy of Acromegaly: A Meta-Analysis, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.8, pp.4465-73, 2005. ,
DOI : 10.1210/jc.2005-0260
(long-acting repeatable octreotide) in the primary therapy of patients with acromegaly, Clinical Endocrinology, vol.29, issue.6, pp.859-68, 2007. ,
DOI : 10.1210/jc.85.2.781
surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study, Clin Endocrinol, vol.70, issue.5, pp.757-68, 2009. ,
Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.4, 2014. ,
DOI : 10.1210/jc.2013-3318
Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly, PLoS ONE, vol.94, issue.8 Suppl 1, p.36411, 2012. ,
DOI : 10.1371/journal.pone.0036411.s002
Significant tumour shrinkage after 12??months of lanreotide Autogel-120??mg treatment given first-line in acromegaly, Clinical Endocrinology, vol.68, issue.2, pp.237-282, 2009. ,
DOI : 10.1111/j.1365-2265.2008.03503.x
Effects of Initial Therapy for Five Years with Somatostatin Analogs for Acromegaly on Growth Hormone and Insulin-Like Growth Factor-I Levels, Tumor Shrinkage, and Cardiovascular Disease: A Prospective Study, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.10, pp.3746-56, 2009. ,
DOI : 10.1210/jc.2009-0941
High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial, European Journal of Endocrinology, vol.161, issue.2, pp.331-339, 2009. ,
DOI : 10.1530/EJE-09-0372
Somatostatin analogs and gallstones: A retrospective survey on a large series of acromegalic patients, Journal of Endocrinological Investigation, vol.338, issue.2, pp.704-714, 2008. ,
DOI : 10.1007/BF03346419
Glucose Tolerance and Somatostatin Analog Treatment in Acromegaly: A 12-Month Study, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.8, pp.2907-2921, 2009. ,
DOI : 10.1210/jc.2008-2627
Hyperglycemia Associated With Pasireotide: Results From a Mechanistic Study in Healthy Volunteers, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.8, pp.3446-53, 2013. ,
DOI : 10.1210/jc.2013-1771
Optimizing Control of Acromegaly: Integrating a Growth Hormone Receptor Antagonist into the Treatment Algorithm, The Journal of Clinical Endocrinology & Metabolism, vol.88, issue.10, pp.4759-67, 2003. ,
DOI : 10.1210/jc.2003-030518
Growth Hormone Receptor Antagonists, The Journal of Clinical Endocrinology & Metabolism, vol.89, issue.4, pp.1503-1514, 2004. ,
DOI : 10.1210/jc.2002-022049
Lessons from 6 years of GH receptor antagonist therapy for acromegaly, J Endocrinol Invest, vol.26, pp.44-52, 2003. ,
Lowering Total Plasma Insulin-Like Growth Factor I Concentrations by Way of a Novel, Potent, and Selective Growth Hormone (GH) Receptor Antagonist, Pegvisomant (B2036-Peg), Augments the Amplitude of GH Secretory Bursts and Elevates Basal/Nonpulsatile GH Release in Healthy Women and Men, Journal of Clinical Endocrinology & Metabolism, vol.86, issue.7, pp.3304-3314, 2001. ,
DOI : 10.1210/jc.86.7.3304
Growth Hormone Receptor Antagonists: Discovery, Development, and Use in Patients with Acromegaly, Endocrine Reviews, vol.23, issue.5, pp.623-669, 2002. ,
DOI : 10.1210/er.2001-0022
Long-term experience of pegvisomant therapy as a treatment for acromegaly, Clinical Endocrinology, vol.90, issue.1, pp.86-91, 2009. ,
DOI : 10.1111/j.1365-2265.2008.03469.x
Long-term treatment with pegvisomant for acromegaly: a 10-year experience, Clinical Endocrinology, vol.154, issue.Suppl 3, pp.540-50 ,
DOI : 10.1111/cen.12993
Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance, European Journal of Endocrinology, vol.154, issue.3, pp.467-77, 2006. ,
DOI : 10.1530/eje.1.02112
Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study, European Journal of Endocrinology, vol.161, issue.1, pp.27-35, 2009. ,
DOI : 10.1530/EJE-08-0910
Tumor Volume of Growth Hormone-Secreting Pituitary Adenomas during Treatment with Pegvisomant: A Prospective Multicenter Study, The Journal of Clinical Endocrinology & Metabolism, vol.95, issue.2, 2010. ,
DOI : 10.1210/jc.2009-1239
Somatotroph Tumor Progression during Pegvisomant Therapy: A Clinical and Molecular Study, The Journal of Clinical Endocrinology & Metabolism, vol.96, issue.2, pp.251-260, 2011. ,
DOI : 10.1210/jc.2010-1742
Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy, Pituitary, vol.342, issue.3, pp.283-292, 2007. ,
DOI : 10.1007/s11102-007-0042-x
Long-term effects of pegvisomant in patients with acromegaly, Nature Clinical Practice Endocrinology & Metabolism, vol.90, issue.6, pp.324-356, 2008. ,
DOI : 10.1038/ncpendmet0831
Evaluation of growth hormone (GH) action in mice: Discovery of GH receptor antagonists and clinical indications, Molecular and Cellular Endocrinology, vol.386, issue.1-2, pp.34-45, 2014. ,
DOI : 10.1016/j.mce.2013.09.004
Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline, Journal of Endocrinological Investigation, vol.92, issue.6, pp.1017-1047, 2014. ,
DOI : 10.1007/s40618-014-0146-x
Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert's syndrome, J Clin Endocrinol Metab, 2010. ,
Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis, European Journal of Endocrinology, vol.154, issue.2, 2006. ,
DOI : 10.1530/eje.1.02079
Combination treatment with somatostatin analogues and pegvisomant in acromegaly, Growth Hormone & IGF Research, vol.21, issue.3, pp.129-162, 2011. ,
DOI : 10.1016/j.ghir.2011.03.004
A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly, Clinical Endocrinology, vol.87, issue.4, pp.549-57, 2009. ,
DOI : 10.1111/j.1365-2265.2009.03620.x
Circulating levels of pegvisomant and endogenous growth hormone during prolonged pegvisomant therapy in patients with acromegaly, Clinical Endocrinology, vol.51, issue.Suppl 1 ,
DOI : 10.1111/cen.12239
Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study, Clinical Endocrinology, vol.113, issue.6, pp.883-90, 2014. ,
DOI : 10.1111/cen.12440
Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant, European Journal of Endocrinology, vol.149, issue.6, pp.521-528, 2003. ,
DOI : 10.1530/eje.0.1490521
Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA, Pituitary, vol.52, issue.3, pp.227-259, 2007. ,
DOI : 10.1007/s11102-007-0037-7
Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly, Pituitary, vol.145, issue.9, pp.196-205, 2009. ,
DOI : 10.1007/s11102-008-0157-8
Intraindividual variation in serum thyroid hormones, parathyroid hormone and insulin-like growth factor-1, Annals of Clinical Biochemistry, vol.45, issue.2, pp.167-176, 2008. ,
DOI : 10.1258/acb.2007.007103
Resistance to Somatostatin Analogs in Acromegaly, Endocrine Reviews, vol.32, issue.2, pp.247-71 ,
DOI : 10.1210/er.2010-0002
One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide AutogelR, Clinical Endocrinology, vol.143, issue.6, pp.734-774, 2004. ,
DOI : 10.1001/archinte.151.8.1573
Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR??, Growth Hormone & IGF Research, vol.18, issue.5, pp.389-93, 2008. ,
DOI : 10.1016/j.ghir.2008.02.001
Effects of octreotide on lipid metabolism in acromegaly. Horm Metab Res Horm Stoffwechselforschung Horm Métabolisme, pp.397-400, 1992. ,
Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels, European Journal of Endocrinology, vol.171, issue.1, pp.59-68 ,
DOI : 10.1530/EJE-13-0438
Gender, Body Weight, Disease Activity, and Previous Radiotherapy Influence the Response to Pegvisomant, The Journal of Clinical Endocrinology & Metabolism, vol.92, issue.1, pp.190-195, 2007. ,
DOI : 10.1210/jc.2006-1412
Growth hormone-binding protein related immunoreactivity is regulated by the degree of insulinopenia in diabetes mellitus, Clinical Endocrinology, vol.44, issue.6, pp.673-681, 1996. ,
DOI : 10.1046/j.1365-2265.1996.672494.x
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients. Pituitary, pp.253-261, 2011. ,
Growth hormone receptor antagonist improves insulin resistance in acromegaly, Growth Hormone & IGF Research, vol.12, issue.6, pp.418-442, 2002. ,
DOI : 10.1016/S1096-6374(02)00083-7
Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly, Clinical Endocrinology, vol.56, issue.3, pp.303-314, 2002. ,
DOI : 10.1001/archinte.151.8.1573
Growth hormone and hepatic lipoprotein metabolism, Current Opinion in Lipidology, vol.5, issue.3, pp.160-165, 1994. ,
DOI : 10.1097/00041433-199405030-00002
Retrospective study single center about 29 acromegaly patients operated or not, not controlled after treatment with SSA first or second generation (IGF- 1> 1 ULN) ,
02) were significantly improved after introduction of PEGV. There was no increase in the size of the adenoma. Moderate liver enzyme elevations (> 3 ULN) ,